New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
07:43 EDTAEZSAeterna Zentaris signs co-promotion services agreement with ASCEND Therapeutics
Aeterna Zentaris announced a strategic co-promotion services agreement with ASCEND Therapeutics US. Under the terms of the agreement, expected to start in the Q4, Aeterna Zentaris will use its newly established commercial structure to market, in specific U.S. territories, ASCEND's EstroGel a non-patch transdermal, FDA approved and commercialized estrogen replacement therapy. For its part, ASCEND would market, in specific U.S. territories, MacrilenTM, Aeterna Zentaris' product for use in the evaluation of adult growth-hormone deficiency for which a New Drug Application is currently under review by the FDA, with a Prescription Drug User Fee Act date of November 5. In consideration for these co-promotion services, each party will be entitled to receive, from the other party, commissions on net sales of each other's product.
News For AEZS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
07:32 EDTAEZSAeterna Zentaris says Macrilen study in AGHD meets EMA study-design expectations
Aeterna Zentaris announced that it has received written scientific advice from the European Medicines Agency regarding the further development plan, including the study design, for the new confirmatory Phase 3 clinical study of Macrilen for use in evaluating adult growth hormone deficiency, following a Scientific Advice Meeting that was held earlier this month. As a result of the advice, the company believes that the confirmatory Phase 3 study that was discussed with the U.S. Food & Drug Administration last March, meets the EMA's study-design expectations. "We are committed to moving forward swiftly with the development of Macrilen in AGHD. We believe that completion of the confirmatory Phase 3 study and the QT study will take 15 to18 months and will require a combined expenditure of between $5M-$6M. We have the resources necessary to bring this product to market and intend to do so as rapidly as possible, pending regulatory approvals," said David Dodd, Chairman and CEO.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use